Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbetocin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR known ✓ | P30559 | 15/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 11/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 10/20 | 1.00 |
| ▸ | AVPR1B | P47901 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbetocin SCHEMBL28528620 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL19712191 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118157 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL19745049 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL3128368 | 0.98 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118135 | 0.97 | OXTR (0.94) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118146 | 0.97 | OXTR (0.94) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118116 | 0.97 | OXTR (0.94) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118144 | 0.96 | OXTR (0.93) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118109 | 0.96 | OXTR (0.92) | OXTRAVPR1AAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2416 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4731243-A2 | IN SITU THERAPEUTIC PRODUCTION: METHODS AND COMPOSITIONS | William Marsh Rice University (US) | 2026-04-29 | — | — | EP | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| WO-2025245322-A1 | OXYTOCIN-BASED THERAPEUTICS TO IMPROVE COGNITIVE CONTROL IN INDIVIDUALS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | THE GENERAL HOSPITAL CORPORATION (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-3852723-B1 | STABLE INTRANASAL FORMULATIONS OF CARBETOCIN | ACADIA PHARM INC (US) | 2025-11-05 | — | — | EP | claimed |
| WO-2025227105-A1 | CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| EP-4601697-A2 | A FORMULATION FOR ORAL DELIVERY OF PEPTIDES AND BIOSIMILARS FOR SYSTEMIC ABSORPTION AND METHOD OF MANUFACTURING THE SAME | NBI Biosciences Pvt Ltd (IN) | 2025-08-20 | — | — | EP | claimed |
| US-20250241981-A1 | NOVEL COMPOSITION | ARECOR LIMITED (GB) | 2025-07-31 | — | — | US | claimed |
| CN-1143911-A | Stabilized composition for oral administration of peptides | FERRING AB (NL) | 1997-02-26 | — | — | CN | claimed |
| EP-0752877-A1 | STABILIZED COMPOSITION FOR ORAL ADMINISTRATION OF PEPTIDES | FERRING B.V. (NL) | 1997-01-15 | — | — | EP | claimed |
| CN-1135603-A | Method for making fifteen kinds of test paper for quickly testing common chemical contamination in food | NANJING RAIWAY MEDICAL COLLEGE (CN) | 1996-11-13 | — | — | CN | claimed |
| CN-1126440-A | Stabilized pharmaceutical peptide compositions | FERRING AB (SE) | 1996-07-10 | — | — | CN | claimed |
| EP-0710122-A1 | STABILIZED PHARMACEUTICAL PEPTIDE COMPOSITIONS | FERRING B.V. (NL) | 1996-05-08 | — | — | EP | claimed |
| US-5482931-A | STORAGE STABILITY; BUFFER, PRESERVATIVE OR DISINFECTANT, AND OSMOTIC PRESSURE-CONTROLLING AGENT | FERRING AB (SE) | 1996-01-09 | — | — | US | claimed |
| EP-0689452-A1 | COMPOSITION FOR ORAL ADMINISTRATION OF PEPTIDES | FJELLESTAD-PAULSEN, Anne (FR) | 1996-01-03 | — | — | EP | claimed |
| WO-1995025534-A1 | STABILIZED COMPOSITION FOR ORAL ADMINISTRATION OF PEPTIDES | FJELLESTAD PAULSEN ANNE (FR) | 1995-09-28 | — | — | WO | claimed |
| WO-1995001185-A1 | STABILIZED PHARMACEUTICAL PEPTIDE COMPOSITIONS | FERRING B.V. (NL) | 1995-01-12 | — | — | WO | claimed |
| WO-1994021286-A1 | COMPOSITION FOR ORAL ADMINISTRATION OF PEPTIDES | FJELLESTAD PAULSEN ANNE (FR) | 1994-09-29 | — | — | WO | claimed |